Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immuron Limited ADR (IMRN)

Immuron Limited ADR (IMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,849
  • Shares Outstanding, K 5,681
  • Annual Sales, $ 110 K
  • Annual Income, $ -6,260 K
  • 60-Month Beta 2.24
  • Price/Sales 210.51
  • Price/Cash Flow N/A
  • Price/Book 1.42
Trade IMRN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 09/07/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance

Most Recent Stories

More News
IMM124E - May offer a New modality for Inhibition of SARS-CoV-2

Key Points

IMRN : 4.55 (+9.64%)
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today...

JPM : 163.04 (+1.15%)
IMRN : 4.55 (+9.64%)
Immuron SARS-CoV-2 Research Agreement with Monash University

Key Points

IMRN : 4.55 (+9.64%)
Immuron Receives AUD $358,280 R&D Tax Concession Refund

Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased...

IMRN : 4.55 (+9.64%)
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine

Key Points

IMRN : 4.55 (+9.64%)
Immuron Travelers' Diarrhea Market Update

Key Points

IMRN : 4.55 (+9.64%)
Nonalcoholic Steatohepatitis Therapeutics Market Outlook 2025 Opportunity and Growth Analysis with Top Key Vendors

The market study on the published by demonstrates the important aspects that are anticipated to shape the growth of the global Nonalcoholic Steatohepatitis Therapeutics market in the upcoming years....

GLMD : 3.05 (+0.33%)
GNFTF : 3.7100 (-6.08%)
GILD : 71.19 (-0.70%)
IMRN : 4.55 (+9.64%)
ICPT : 16.06 (-1.71%)
NVO : 100.70 (-1.37%)
TBRA : 42.09 (+0.65%)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Market 2020 with COVID-19 Impact Analysis

report by Marketinsightsreports offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Clostridium Difficile Infections (Clostridium Difficile...

IMRN : 4.55 (+9.64%)
MRK : 73.61 (+0.77%)
NVS : 82.93 (-0.77%)
VRX.TO : 30.80 (-3.33%)
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense

Key Points

IMRN : 4.55 (+9.64%)
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea

Key Points

IMRN : 4.55 (+9.64%)

Business Summary

Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale,...

See More

Key Turning Points

3rd Resistance Point 6.22
2nd Resistance Point 5.71
1st Resistance Point 5.13
Last Price 4.55
1st Support Level 4.04
2nd Support Level 3.53
3rd Support Level 2.95

See More

52-Week High 5.20
Fibonacci 61.8% 4.74
Fibonacci 50% 4.60
Last Price 4.55
Fibonacci 38.2% 4.46
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar